Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Capricor Therapeutics (CAPR) over the last 16 years, with Q3 2025 value amounting to $6950.0.

  • Capricor Therapeutics' Cash from Financing Activities fell 9998.97% to $6950.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $81.2 million, marking a year-over-year decrease of 1442.96%. This contributed to the annual value of $152.8 million for FY2024, which is 49723.24% up from last year.
  • Latest data reveals that Capricor Therapeutics reported Cash from Financing Activities of $6950.0 as of Q3 2025, which was down 9998.97% from $19580.0 recorded in Q2 2025.
  • Capricor Therapeutics' 5-year Cash from Financing Activities high stood at $81.1 million for Q4 2024, and its period low was $3895.0 during Q1 2023.
  • For the 5-year period, Capricor Therapeutics' Cash from Financing Activities averaged around $10.7 million, with its median value being $1.9 million (2022).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first surged by 5869958.92% in 2024, then plummeted by 9998.97% in 2025.
  • Quarter analysis of 5 years shows Capricor Therapeutics' Cash from Financing Activities stood at $42370.0 in 2021, then surged by 6861.35% to $2.9 million in 2022, then soared by 685.45% to $23.2 million in 2023, then skyrocketed by 250.01% to $81.1 million in 2024, then crashed by 99.99% to $6950.0 in 2025.
  • Its last three reported values are $6950.0 in Q3 2025, $19580.0 for Q2 2025, and $50354.0 during Q1 2025.